Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation

Angiogenesis

Volumn 3, Issue 3, 1999, Pages 249-257

  Natke, Barbara ^a   Venkataraman, Ganesh ^a   Nugent, Matthew A ^b   Sasisekharan, Ram ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FGF 2; FGFR; Heparin; HLGAG; Smooth muscle cells

Indexed keywords

BOVINAE;

EID: 2342488939     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009008824246     Document Type: Article

References (45)

1. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiolgical processes. Physiol Rev 1991; 71: 481-533.
2. Neufeld G, Tessler S, Gitay-Goren H et al. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5: 89-97.
3. Santamarina-Fojo S, Brewer JB. Lipoprotein lipase: Structure, function and mechanism of action. Int J Clin Lab Res 1994; 24: 143-7.
4. Clarke D, Katoh O, Gibbs RV et al. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine 1995; 7: 325-30.
5. LaRochelle WJ, Sakaguchi K, Atabey N et al. Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. Biochemistry 1999; 38: 1765-71.
6. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/ heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 1993; 263: 23898-905.
7. Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J Biol Chem 1992; 267: 9451-4.
8. Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulfate. J Biol Chem 1998; 273: 24979-82.
9. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from the endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989; 140: 68-74.
10. Foresten KE, Courant NA, Nugent MA. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Phys 1997; 172: 209-20.
11. Rapraeger AC, Guimond S, Krufka A, Olwin BB. Regulation by heparan sulfate in fibroblast growth factor signaling. Meth Enzymol 1994; 245: 219-40.
12. Logan A, Black EG, Gonzalez AM et al. Basic fibroblast growth factor: An autocrine mitogen of rat thyroid follicular cells? Endocrinology 1992; 130: 2363-72.
13. Sasisekharan R, Ernst S, Venkataraman G. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1997; 1: 45-54.
14. Bikfalvi A, Savona C, Perollet C, Javerzat S. New insights in the biology of fibroblast growth factor-2. Angiogenesis 1997; 1: 155-173.
15. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-65.
16. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Frontiers Biosci 1999; 4: 165-77.
17. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
18. Nugent MA, Karnovsky MJ, Edelman ER. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 1993; 73: 1051-60.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
20. Andres V. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int J Mol Med 1998; 2: 81-9.
21. Han RO, Ettenson DS, Koo EWY, Edelman ER. Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells. Am J Physiol 1997; 273: H2586-95.
22. Sasisekharan R, Moses MA, Nugent MA et al. Heparinase inhibits neovascularization. Proc Natl Acad Sci USA 1994; 91: 1524-8.
23. Silver PJ, Moreau J-P, Denholm E et al. Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo. Eur J Pharm 1998; 351: 79-81.
24. Ernst S, Langer R, Cooney CL, Sasisekharan R. Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 1995; 30: 387-444.
25. Nugent MA, Edelman ER. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: A mechanism for cooperactivity. Biochemistry 1992; 31: 8876-83.
26. Lee JC, Hapel AJ, Ihle JN. Constitutive production of a unique lymphokine (IL3) by the WEHI-3 cell line. J Immunol 1982; 128: 2393-8.
27. Davis J, Venkataraman G, Shriver Z et al. Oligomeric self-association of fibroblast growth factor-2 in the absence of heparin-like glycosaminoglycans. Biochem J 1999; 341: 613-20.
28. Fannon M, Nugent MA. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Ba1b/ c3T3 cells in the absence of heparan sulfate. J Biol Chem 1996; 271: 17949-56.
29. Keller KM, Brauer PR, Keller JM. Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate. Biochemistry 1989; 28: 8100-7.
30. Walker A, Turnbull JE, Gallagher JT. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 1994; 269: 931-5.
31. Pye DA, Vives RR, Turnbull JE et al. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 1998; 273: 22936-42.
32. Venkataraman G, Shriver Z, Davis JD, Sasisekharan R. Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Proc Natl Acad Sci USA 1999; 96: 1892-7.
33. Sperinde GV, Nugent MA. Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells. Biochemistry 1998; 37: 13153-64.
34. Heath WF, Cantrell AS, Mayne NG, Jaskunas SR. Mutations in the heparin-binding domains of human basic fibroblast growth factor alter its biological activity. Biochemistry 1991; 30: 5608-15.
35. Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: Identification of the heparin binding domain. Biochemistry 1994; 33: 3831-40.
36. Faham S, Hileman RE, Fromm JR et al. Heparin structure and interactions with basic fibroblast growth factor. Science 1996; 271: 1116-20.
37. Ornitz DM, Yayon A, Flanagan JG et al. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992; 12: 240-7.
38. Ishihara M, Tyrrell DJ, Stauber GB et al. Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 1993; 268: 4675-83.
39. Pye DA, Kumar S. Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor. Biochem Biophys Res Comm 1998; 248: 889-95.
40. Krufka A, Guimond S, Rapraeter AC. Two hierarchies of FGF-2 signaling in heparin: Mitogenic stimulation and high-affinity binding/receptor transphosphorylation. Biochemistry 1996; 35: 11131-41.
41. Tumova S, Hatch BA, Law DJ, Bame KJ. Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products. Biochem J 1999; 337: 471-81.
42. Roghani M, Moscatelli D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 1992; 267: 22156-62.
43. Colin S, Jeanny J-C, Mascarelli F et al. In vivo involvement of heparan sulphate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol 1999; 1: 74-82.
44. Amalrich F, Bouche G, Bonnet H et al. Biochem Pharacol 1994; 47: 111-5.
45. Miyamoto T, Leconte I, Swain JL, Fox JC. Autocrine FGF signaling is required for vascular smooth muscle cell survival in vitro. J Cell Physiol 1998; 177: 58-67.